Abstract
Two chemotherapy regimens for advanced NSCLC given on an outpatient basis were evaluated in a prospective phase II trial: mitomycin, ifosfamide, and cisplatin (MIP) vs vindesine, ifosfamide, and cisplatin (VIP). This study included 100 patients. Prognostic factors were well balanced between the arms. Objective response rates (CR: MIP 0%, VIP 4%; PR: MIP 24%, VIP 18%) and survival (median time: 7 months in both arms) were in the standard range usually reported. Subjective and symptomatic improvement have been assessed. Toxicity was moderate, manageable, and mostly reversible. We believe that investigation for new ambulatory schemes must continue.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Ambulatory Care
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / secondary
-
Cisplatin / administration & dosage
-
Female
-
Humans
-
Ifosfamide / administration & dosage
-
Lung Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Mitomycin
-
Mitomycins / administration & dosage
-
Survival Analysis
-
Vindesine / administration & dosage
Substances
-
Mitomycins
-
Mitomycin
-
Cisplatin
-
Vindesine
-
Ifosfamide
Supplementary concepts
-
MIP protocol
-
VIP protocol 3